Background: Heterozygous gain-of-function mutations in PI3K110d lead to lymphadenopathy, lymphoid hyperplasia, EBV and cytomegalovirus viremia, and sinopulmonary infections.
Natural killer (NK) cells play an important role in host defense, and NK cell deficiency leads to severe and often fatal viral infection and malignancy. [1] [2] [3] [4] Although primary immunodeficiencies (PIDs) leading to isolated NK cell deficiency are relatively rare, currently greater than 40 congenital deficiencies affect NK cell function in a broader immunologic context. 5 Human NK cells play a critical role in control of viral infections through secretion of cytokines and direct, contact-dependent killing of virally infected cells. As such, PIDs that include an effect on NK cell function are caused frequently by mutations in genes that affect the cytolytic machinery of NK cells. These conditions include the familial hemophagocytic lymphohistiocytosis diseases; mutations affecting the cytoskeleton, such as dedicator of cytokinesis 8 6, 7 and Wiskott-Aldrich syndrome, 8, 9 defects in the nuclear factor kB pathway, 10, 11 and others. 5 NK cell killing of virally infected targets is mediated by directed secretion of lytic granules after formation of a lytic immunologic synapse (IS). NK cell IS formation and function include multiple tightly regulated steps, and the perturbation of these checkpoints leads to blunting of the cytotoxic response. NK cell cytotoxicity is controlled through a balance of activating and inhibitory receptor signaling. Overcoming a critical threshold of activating receptor signaling leads to commitment to IS formation, which includes F-actin remodeling and de novo polymerization, polarization of the microtubule organizing center (MTOC) and lytic granules to the IS, and exocytosis of perforin-and granzyme-containing lytic granules. An early priming step in IS formation is the convergence of lytic granules to the MTOC, which occurs in response to diverse activating signals, including cytokine stimulation, integrin ligation, and activating receptor ligation. [12] [13] [14] This step, which is independent of actin remodeling, precedes integrin-mediated firm adhesion and de novo F-actin polymerization, which occurs downstream of activating receptor signaling. Convergence is followed by polarization of the MTOC, which delivers lytic granules to the IS. Lytic granules then traverse the F-actin network at the IS and undergo exocytosis, leading to target cell apoptosis.
The phosphoinositide 3-kinase (PI3K) pathway is a key axis for NK cell cytotoxicity. Signaling downstream from NK cell-activating receptors, such as CD16 and NKG2D, leads to PI3K recruitment and activation through adaptors, including DAP10 and CD3z. [15] [16] [17] [18] [19] [20] Downstream signaling to cytotoxicity is mediated by Rac1, p21-activated kinase 1, mitogen-activated protein kinase kinase, and extracellular signal-regulated kinase (ERK) 1/2. 21 The requirement for PI3K in NK cell cytotoxic function has been shown by using pharmacologic inhibitors, with varying effects depending on the target and killing not being entirely abrogated in all cases. 16, 19 Further insight has been gained by using isoform-specific mouse models to dissect the role of individual subunits in the cytotoxic process. Class 1A PI3Ks in lymphocytes are comprised of a p110 catalytic subunit encoded by the PIK3CA, PIK3CB, or PIK3CD gene and paired with a p85, p55, or p50 regulatory subunit. Catalytic inactivation, specifically of the PI3K110d subunit, in mice leads to reduced NK cell numbers, impaired maturation, and decreased cytotoxic function. 22 The effect of gain-of-function Pik3cd mutations has not been tested directly in mice; however, their effect can be predicted based on loss-of-function mutations in phosphatase and tensin homolog (Pten), which have a similar effect of increasing phosphatidylinositol (3, 4, 5) -trisphosphate (PtdIns [3, 4, 5] P3) levels.
Mutations in PI3K isoforms lead to distinct PIDs. Loss of p85a in human patients leads to loss of B-cell function and subsets. 23 However, gain-of-function mutations in patients with p110d mutations lead to p110d-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency (PASLI) disease 24 or activated phosphoinositide 3-kinase d syndrome 1 (APDS1), 25 which are characterized by EBV and cytomegalovirus viremia in conjunction with T-cell lymphoproliferation and CD8
1 T-cell metabolism defects, lymphopenia, increased IgM levels and circulating transitional B-cell numbers, and recurrent respiratory tract infections. [24] [25] [26] [27] [28] In these patients hyperactive PI3K pathway signaling through protein kinase B (AKT) drives premature senescence of CD8 1 T cells and subsequent loss of CD8 1 T cell-mediated IL-2 secretion, 24 as reviewed by Lucas et al. 29 Hyperactivation of the PI3K pathway leads to increased mammalian target of rapamycin (mTOR) activity and glycolytic function. These effects are counteracted partially by treatment with the mTOR inhibitor rapamycin. Rapamycin treatment of patients with APDS1 results in decreased CD8
1 cellularity and increased IL-2 secretion, which is accompanied by observed clinical improvement of the disease. 24 In this study we identified a family of 3 siblings with E525K mutations in the PIK3CD gene. 30, 31 The 3 affected brothers had clinical and immunologic features consistent with PIK3CD gain-of-function disease, including persistently increased EBV PCR titers, diffuse lymphadenopathy, hepatosplenomegaly, markedly increased transitional B-cell percentages, and poor responses to polysaccharide antigens. Identification of this mutation in these patients afforded us the opportunity to evaluate NK cell function and phenotype before and after initiation of rapamycin treatment. Furthermore, we expanded our cohort to describe NK cell deficiency in 5 previously described patients 24 and 2 additional previously unreported patients.
We show that both E1021K and E525K gain-of-function mutations in PI3K110d lead to functional NK cell deficiency because of decreased frequency of conjugate formation with susceptible target cells and impaired signaling, leading to the execution of cytotoxicity. Furthermore, skewing of the NK cell phenotype occurs, notably with decreased expression of the Fc receptor (CD16) and IL-2 receptor b (CD122) on patients' cells. Following stabilization on rapamycin therapy, a significant improvement in NK cell function was observed, which was reflected by partially corrected immune synapse formation. Therefore we define gain-of-function mutations in PI3K p110d as a novel cause of NK cell functional and developmental impairment and a likely contributor to disease in these patients.
METHODS

Cell isolation and cell lines
All human samples were obtained with written informed donor consent and were used with the approval of the National Institutes of Health and Baylor College of Medicine Institutional Review Boards for the Protection of Human Subjects. All samples were obtained in compliance with the Declaration of Helsinki. PBMCs were isolated by means of density centrifugation over Ficoll-Paque, according to the manufacturer's instructions. For Cr 51 release assays, Raji and K562 cell lines were used as target cells for NK cell cytotoxicity and maintained in supplemented RPMI media with 10% FCS. Target cells were routinely tested and confirmed to be mycoplasma free.
Genetic studies
Whole-exome sequencing for research at Baylor College of Medicine was performed, as previously described. 32 Clinical sequencing was performed by Baylor Genetics. 33, 34 Variants were confirmed by using Sanger sequencing in the Baylor DNA Sequencing Core Facility. Patients from the National Institutes of Health were identified genetically by means of targeted or whole-exome sequencing, as previously described. 24 For deep sequencing, the PIK3CD c.G1573A variant was validated by using amplicon deep sequencing on the MiSeq sequencer (Illumina, San Diego, Calif). Briefly, an amplicon of 234 bp defined by a forward primer of 59-ACCGAGGAGGAGGTGAGTG-39 and a reverse primer of 59-ACTTGGTGACCAGCAGCAG-39 was generated through PCR from 6 genomic DNA samples of the proband and family members by using PrimeSTAR GXL DNA Polymerase (Takara Bio, Otsu, Japan). PCR products were purified with AMPure beads (Beckman Coulter, Fullerton, Calif) and further end-repaired and ligated with TruSeq indexed adaptors. Equal amounts of ligated amplicons were pooled and sequenced by using the MiSeq Nano Kit v2 for 300 cycles with PhiX spike-in. Raw sequencing data were demultiplexed and converted to Fastq files. Reads were then aligned to human genome assembly 37/hg19 reference sequence by using BWA-MEM (Burrows-Wheeler Aligner-MEM Tool). Variants were called, and numbers of variants read were counted from each demultiplexed sample.
Cr 51 release assays
Chromium release assays for analysis of NK cell activity were performed, as previously described. 35 Freshly isolated PBMCs were incubated at varying ratios (50:1, 25:1, 12.5:1, 6.25:1, and 3.13:1) with 10 4 K562 or Raji target cells that had been labeled with 50 mCi of Cr 51 and then washed. Where indicated, assays were performed in the presence of 1000 U/mL IL-2 (Roche, Mannheim, Germany) or, as a stimulus for antibody-mediated cytotoxicity, 20 mg/mL rituximab. Effector-target conjugates were incubated in 200 mL in round-bottom 96-well plates (Corning, Corning, NY). After 4 hours of incubation, positive controls for maximal lysis were produced by lysing labeled target cells with 1% octylphenoxypolyethoxyethanol. Supernatants were harvested and transferred to LumaPlates (PerkinElmer, Waltham, Mass). The supernatant was dried, and plates were read on a TopCount gamma counter (PerkinElmer). The percentage of specific lysis was calculated as follows: ðExperimental release2Spontaneous releaseÞ=Maximum release Ã 100:
Lytic units were calculated as the number of effectors required to lyse 10% of K562 target cells by using the slope of the curves generated by using cytotoxicity assay data over the range of effector/target ratios. 8 
Flow cytometry
Multiparametric flow cytometry was done with the antibodies described in Table E1 Images were taken in a single Z-plane. Images were acquired and analyzed with Volocity 6.0 software (PerkinElmer). Image analysis was performed as described for F-actin accumulation, lytic granule convergence, and MTOC polarization. [37] [38] [39] Briefly, F-actin accumulation at the synapse was calculated with Volocity software (PerkinElmer) by measuring the intensity and area of F-actin above a uniform threshold. Cortical actin from both effector and target cells was subtracted from F-actin at the synapse so that only specific F-actin accumulation was measured. 38 For measurement of granule convergence, centroids of lytic granules were detected based on perforin intensity, and the MTOC was detected based on the intensity of tubulin immunostaining. The distance of granules to the MTOC was measured for each granule by using Volocity software; each data point represents the mean of all granules within a given cell. 39 
Graphing and statistical analysis
Pairwise comparisons were made by using the Student 2-tailed t test. For cytotoxicity assays, conditions were compared by using ordinary 1-way ANOVA with post hoc analysis by using the Tukey multiple comparisons test. For conjugation assays, statistical outliers were identified by using ROUT analysis (1%) and excluded from analysis. All graphing and statistical analysis was performed with Prism 6.0 software (GraphPad Software, La Jolla, Calif).
RESULTS
Clinical history and genetic confirmation of PI3K110d mutation
The index family consists of 3 brothers from Qatar who presented at 9 years, 5 years, and 1 year of age, respectively, because of diffuse lymphadenopathy, hepatosplenomegaly, and persistently increased EBV PCR titers. X-linked lymphoproliferative disease, autoimmune lymphoproliferative syndrome, and hemophagocytic lymphohistiocytosis were excluded, and the family returned to Qatar without a formal diagnosis. They returned 4 years later for further evaluation. The older brother had bronchiectasis and mild pulmonary fibrosis in the interim caused by recurrent pneumonias. They otherwise denied any other recurrent infections. The parents denied consanguinity, and the 3 siblings had 2 other older twin brothers who were healthy. Immunologically, the 3 affected boys had markedly increased transitional B-cell percentages and poor antibody responses to polysaccharide antigens. Whole-exome sequencing was performed and revealed the presence of a heterozygous missense PIK3CD E525K mutation in the 3 affected brothers; the 2 twin siblings carried wild-type PIK3CD sequences (see Table E2 in this article's Online Repository at www.jacionline. org for other variants found at low frequency within the EXaC database).
The father was noted to have 6 variant reads out of 38 total reads, which is suggestive of mosaicism 30, 31 or heterozygosity. Because the resolution of Sanger sequencing did not permit us to determine whether the father was truly heterozygous (see Fig  E1, A, in this article's Online Repository at www.jacionline. org), we performed deep sequencing of the region of interest, generating more than 200,000 reads (see Fig E1, B) . This analysis confirmed the presence of the heterozygous mutation in the 3 affected siblings and homozygosity of the wild-type allele in the unaffected brothers. The father was also found to have full heterozygosity at this locus, with 49% of reads having the mutation present in the affected children. Unfortunately, the father was not available for further immunologic evaluation. It is regrettable that further clinical information about the father was not available because this would additionally demonstrate the pathogenicity of the mutation shared by the father and the patients; however, previous reports of the PIK3CD E525K mutation as disease-causing with high penetrance 24 underscore the likelihood that there is a clinical effect of this mutation in affected family members.
We identified further subjects with PIK3CD mutations. First, we were introduced to a 5-year-old asymptomatic boy who had 10 is normalized to the healthy donor control subject for each assay. C, PBMCs isolated from healthy donors (circles, n 5 10), patients with PI3K110d E525K mutations (squares, n 5 4), or patients with PI3K110d E1021K mutations (triangles, n 5 2) were incubated with patient Raji B cells in the presence of 20 mg/mL rituximab. Cytotoxicity was measured by using the Cr 51 release assay. ADCC, Antibody-mediated cellular cytotoxicity; E:T, effector/target ratio.
clinical whole-exome sequencing performed due to mild developmental delay. The results incidentally revealed the presence of a single heterozygous E1021K mutation in PIK3CD, which was confirmed by means of clinical Sanger sequencing. This subject was also noted to have an increased transitional B-cell percentage (>20% of CD19 1 B cells) and lack of response to polysaccharide antigens. Serologic and PCR testing showed that he had never been exposed to EBV.
Next, we obtained samples from 5 previously reported subjects and 1 unreported subject who had PIK3CD mutations identified by means of whole-exome or targeted sequencing. 24 Three of the 6 subjects carried the E525K mutation, 2 had the E1021K mutation, and 1 had the N334K mutation (summarized in Table I ). As previously described, 24 ,25 the E1021K mutation is located within the kinase domain of PI3K110d, and the E525K mutation is found within the helical domain (see Fig E1, C) . PI3K110d mutation leads to altered NK cell subset distribution. Flow cytometric data from 8-color analysis of NK cell-surface receptors were associated with developmental subsets on a healthy donor (top) and 2 patients with PI3K110d E525K mutations (bottom) and were visualized by using SPADE. The gating strategy for each patient or control subject is shown at left with the frequency of NK cells within the lymphocyte gate. Clustering parameters are shown in the center. SPADE plot node sizes and intensities are based on cell counts, as shown in the heat map legend.
NK cells from patients with PI3K110d mutations have decreased natural and antibody-mediated cytotoxicity NK cells from PI3K110d mutant mice have decreased natural cytotoxicity, 22, 40 and patients with PASLI/APDS1 show susceptibility to viral infection. Because NK cells participate in antiviral defense, we tested the function of patients' NK cells by using Cr 51 release assays against susceptible K562 target cells in the presence or absence of IL-2. Patients showed decreased cytotoxic function, although interestingly, stratification based on mutation was observed for both unstimulated and IL-2-stimulated cells (Fig 1, A) . Patients with E525K and PBMCs from 5 healthy donors (black circles) and patients with PI3K110d E525K (red squares), E1021K (blue squares), or N334K (green squares) mutations were analyzed by using flow cytometry, as shown in Fig 2. A and B, NK cell frequency (Fig 3, A) and CD56 bright subset distribution (Fig 3, B) . C, NK cell receptor expression on CD56 bright and CD56 dim subsets, as indicated. *P < .05, Student 2-tailed t test. HD, Healthy donor; N.S., not significant.
N334K mutations had a greater reduction in NK cell lytic function than those with E1021K mutations relative to grouped healthy control subjects. Although the response to IL-2 was varied, a relative increase in cytolytic function in response to IL-2 was noted (Fig 1, A and B) . We further evaluated the cytolytic capacity of patients' NK cells by calculating lytic units required to lyse 10% of K562 target cells after adjustment for the frequency of NK cells within the PBMC population (Fig 1, B) . With the exception of patient 5, NK cells had reduced lytic capacity when directly compared with those of the healthy donor control subjects used for their respective assays.
To determine the effect of PI3K110d mutation on antibody-mediated cellular cytotoxicity, Raji target cells were coated with rituximab, and cytotoxicity assays were performed as above. Although Raji cells in the absence of antibody were not lysed (data not shown), the presence of antibody led to effective killing of targets by control subjects. However, NK cells from patients with E525K and E1021K mutations had significantly decreased function (Fig 1,  C) . Taken together, these results show impaired NK cell function in patients with gain-of-function PI3K110d mutations, producing significantly reduced cytolytic function toward both susceptible tumor cells and antibody-coated targets.
PI3K110d mutation leads to skewed NK cell developmental phenotypes in human NK cells
Patients with PI3K110d gain-of-function mutations have some variability in NK cell numbers and altered T-cell subsets due to premature senescence. 24, 26 In addition, alteration of PI3K function in mice is known to lead to reduced NK cell numbers with abnormal NK cell developmental subsets. 22, 40 To fully explore the NK cell phenotype in these patients, we performed quantitative flow cytometry with 5 panels assessing 40 parameters, including NK cell-surface receptors, intracellular cytokines, and markers of NK cell activation (see Table E1 ). To visually compare the distribution of phenotypic subsets between healthy donor and patient samples and to identify novel populations, we performed visual SPADE. 41 Analysis was performed on flow cytometric data of 8 key NK cell maturation markers after gating for CD56
1
CD3
2 NK cells from 2 patients with E525K mutations and 5 healthy donors from 3 independent experiments. Consistently, patients 1 and 3 (E525K mutation) had unique subsets preserved between the 2 patients who were not seen in healthy donors (Fig 2) . Healthy donor populations from 5 subjects were remarkably similar when visualized by using SPADE given the known intraindividual heterogeneity in NK cell subsets (Fig 2, data not shown) . 42, 43 Guided in part by our SPADE analysis that identified visually distinct subsets within patients' NK cell populations, we defined markers from our panels that were differentially expressed on cells from patients compared with those from healthy control subjects. To quantitatively compare these, we performed pairwise analyses of frequency of receptor expression (percent positive) on NK cells. Because CD56 bright and CD56 dim NK cells represent phenotypic and functional subsets and CD56 bright NK cells are thought to be the developmental precursors of CD56 dim NK cells, we quantified expression on these subsets individually. As previously described, we saw significant reductions in NK cell numbers in many patients with PI3K110d mutations (Fig 3,  A) . 24, 26 Although the frequencies of CD56 bright cells in patients were normal (Fig 3, B) , skewing of the NK cell phenotype toward a generally immature one was present, with a decrease in CD16 and increase in NKG2A expression on CD56 dim NK cells (Fig 3, C) . Furthermore, CD62L and CD127 expression was decreased on CD56 bright NK cells, and CD122 expression was diminished on both subsets (Fig 3, C) . In contrast to the phenotype observed in the mouse model, no detectable difference in CD27 expression was observed on patients' NK cells (data not shown). 22 Granzyme B and CD57 were also unchanged between patient and healthy donor cells in contrast to the phenotype of effector T cells in these patients. 24 Intracellular IFN-g expression in response to PMA/ionomycin stimulation was lower in patients' NK cells, although not significantly. Although TNF-a expression was also not affected, a significant decrease in GM-CSF expression by patients' NK cells was observed (see Fig E2 in this article's Online Repository at www.jacionline.org).
Taken together, these results indicate an alteration in NK cell phenotype or activation state. These effects are independent of global NK cell development when taken in light of the normal distribution of CD56 bright and CD56 dim subsets. Furthermore, they are distinct from effects on both murine NK cells and human CD8
1 effector cells, which have unique markers affected by PI3K110d mutation. Collectively, however, these significant alterations in NK cell phenotype provide interesting insight into the loss of cytotoxic function in patients' NK cells.
Impaired conjugate formation, ERK phosphorylation, and lytic machinery polarization in PI3K110d NK cells
To further probe the mechanism of cytotoxic dysfunction, we sought to identify the affected stage or stages of NK cell-mediated killing of target cells in patients with PI3K110d mutations. The initial stage of NK cell cytotoxicity is recognition and conjugate formation, leading to firm adhesion. 44 Given the requirement for F-actin rearrangement in conjugate formation and the potential effect of deregulated PI3K activity on this pathway, we analyzed the frequency of NK-target cell conjugate formation by using fluorescence-activated cell sorting. Differentially labeled NK cells and targets were mixed and allowed to form conjugates for 0, 10, 20, 30, and 60 minutes. Despite comparable expression of integrins and activating receptors between healthy donor and patients' cells (data not shown), NK cells from patients with PI3K110d mutations showed a trend toward lower conjugate formation that was significant in patients with E1021K mutations at later time points (60 minutes: healthy donors, 6.8% 6 1.9%; patients with E525K mutations, 4.4% 6 0.7%; patients with E1021K mutations, 1.9% 6 0.4%; P < .05, 1-way ANOVA; Fig 4, A) .
PI3K110d catalytically inactive mutant mice show impaired signaling in the mitogen-activated protein kinase pathways, specifically phosphorylation of c-Jun N-terminal kinase (JNK) 1/2, 22 and Pik3cd 2/2 Pik3cg 2/2 mice have defective ERK1/2 signaling. 40 To test this pathway in patients' cells, we performed intracellular fluorescence-activated cell sorting for phosphorylated ERK1/2, JNK1/2, and p38 after NK cell activation by PMA and ionomycin. Although phosphorylation of JNK1/2 and p38 was intact in patients' cells, the percentage of NK cells with ERK1/2 phosphorylation was significantly reduced in patients with both E525K and E1021K mutations 15 minutes after activation (healthy donors, 43.3% 6 9.2%; patients with E525K mutations, 7.2% 6 2.2%; patients with E1021K mutations, 9.2% 6 1.4%; P < .05, 1-way ANOVA; Fig 4, B) .
Upon conjugate formation and activating signaling, NK cells rapidly converge lytic granules to the MTOC, followed by the effector stage of cytotoxicity, which is marked by accumulation of F-actin and polarization of lytic granules and the MTOC to the IS. 39, 44 To further investigate the effect of impaired PI3K110d signaling on NK cell lytic function, we performed quantitative analysis of the polarization of lytic machinery in NK cells conjugated to susceptible target cells and imaged by using confocal microscopy (Fig 4, C) . Although healthy donor NK cells had accumulation of F-actin after conjugation to target cells, aggregation of F-actin at the IS was significantly decreased in all patients' cells tested, regardless of mutation (Fig 4, D) . Furthermore, significant defects in the convergence of lytic granules to the MTOC and MTOC polarization were present in the E525K cohort (Fig 4, D) . Interestingly, these parameters were not affected significantly in patients with the E1021K mutation.
Partial increase in NK cell function after initiation of treatment with rapamycin
Rapamycin treatment has proved relevant for the amelioration of symptoms in patients with PI3K110d mutations. 24 To determine the specific effect of treatment on NK cell function, we evaluated NK cell cytotoxicity in 3 patients before initiation of rapamycin and after establishment of treatment. Although NK cell numbers increased in 1 patient only (Fig 5, A) and the cell-surface receptor phenotype was not significantly changed (data not shown), improvement in specific lysis of K562 target cells was seen in all 3 patients (Fig 5, B) . When normalized to healthy donor control subjects, the mean specific lysis at an effector/target ratio of 50:1 for all 3 patients increased from 0.14 6 0.01 to 0.49 6 0.1 (P < .01; Fig 5, B) . Finally, to ascertain whether this increase in cytotoxic function correlated with a restoration of previously impaired effector mechanism, we re-evaluated NK-target conjugates using confocal microscopy. We found that after the establishment of rapamycin therapy in the patients, who had all failed to accumulate F-actin at the synapse previously, we now observed that F-actin rearrangement was comparable with that of healthy donor control subjects (Fig 5, C) . Therefore the increase in NK cell function after mTOR inhibition in patients with PI3K110d mutations occurs in concert with restoration of cytolytic machinery.
DISCUSSION
The PI3K signaling axis is an important one in NK cell biology, as demonstrated by studies in both mouse 22, 40 and human subjects. [24] [25] [26] In particular, the PI3K signaling pathway is required for the development of NK cells in mice 22, 40 and the polarization of lytic machinery during human NK cell-mediated killing of target cells. 45 The recent description of patients with gain-of-function mutations in PIK3CD highlights the importance of balanced signaling through this pathway in human health because these patients have severe lymphoproliferative disease and immunodeficiency. The prevalence of EBV disease, a hallmark of NK cell dysfunction, and the documented role for this signaling pathway in NK cell function led us to investigate further the functional and developmental phenotype of NK cells in these patients. Here we show that in addition to the reduced NK cell numbers seen in some patients with PI3K110d mutations, 24, 26 significant impairments in NK cell phenotype and function exist in patients with PIK3CD gain-of-function mutations.
Previous studies of murine models have revealed both developmental and functional abnormalities in NK cells after disruption of PI3K110d. Loss of PI3K110d function leads to reduced NK cell numbers in the periphery and an immature phenotype when combined with loss of the PI3K110g subunit. 40 Catalytically inactive PI3K110d results in a similar phenotype, with a block in NK cell development leading to decreased NK cell numbers and a specific decrease in the CD27 hi mature population. 22 In both previous studies, developmental defects were accompanied by specific loss of NK cell function because impairment in JNK1/2 and ERK1/2 activation leads to defective in vitro and in vivo tumor clearance. 22, 40 We have now demonstrated that hyperactive PI3K110d function in human subjects leads to NK cell derangements.
The careful examination of the NK cell phenotype in patients with PI3K110d mutations shows select developmental defects. Interesting conserved defects were observed between the gain-offunction mutations in our patients and murine loss-of-function models. This semblance includes the immature NK cell phenotype seen in patients' cells, although this defect is not as absolute as the halt in NK cell development seen in the mouse model. 22 The presence of CD27 on patients' cells at comparable levels to healthy donors is a notable difference between gain-and loss-of-function mutations, although the significant divergence between mice and human subjects in terms of NK cell development can also account for this discrepancy.
Although human NK cells are defined largely phenotypically and functionally by CD56 density, with CD56 bright being the cytokine-producing subset and CD56 dim being the predominantly cytotoxic subset, murine NK cells do not express a CD56 homologue. Because human NK cells are thought to pass first through the CD56 bright stage and then mature to the CD56 dim stage, it has been difficult to completely correlate these stages in the mouse. However, a surrogate scheme based on CD27 and CD11b (Mac-1) density has been designed in terms of function, 46 and thus the lack of CD27 hi NK cells in the mouse model is reflective of a block in maturation. That said, the relative frequency of CD56 bright and CD56 dim cells was not directly affected as a result of gain-of-function mutations in the patients we examined. Instead, other very consistent differences were observed that indicated a less mature NK cell functional phenotype as a result of gain-of-function mutations in patients' NK cells.
These phenotypic changes were initially illuminated by using SPADE analysis, which showed unique NK cell subsets in patients' cells relative to cells from healthy donors. Further analysis showed a generally immature CD56 dim population, with decreased CD16 and increased NKG2A expression. Interestingly, both CD56 bright and CD56 dim subsets had decreased CD122 expression, which could indicate that at least some of the functional hyporesponsiveness shown by patients' NK cells is due to decreased IL-2 mediated activation. Although CD56 dim NK cells appeared less mature, the CD56 bright NK cells in our patients had decreased CD62L and CD127 receptors, and it would be of interest to determine whether patients' T cells were similarly affected and whether this decreased expression contributes to the T-cell phenotype seen in these patients. [24] [25] [26] Of note, CD56 bright NK cells appeared to have normal cytokine production, including IFN-g, on stimulation, and levels of granzyme B were not affected, unlike in cytotoxic T lymphocytes. 24 The significance of the differences between mutations is not entirely clear. Although both E525K and E1021K result in impaired NK cell cytotoxic function and seemingly similarly affect NK cell number and phenotype, the E1021K mutation had a significant effect on conjugate formation, whereas the E525K mutation had a greater effect on polarization of lytic machinery after conjugate formation. The E1021K mutation, which is located in the kinase domain, has been shown to increase membrane association and kinase activity. 25, 47 In contrast, both N334K and E525K mutations interrupt inhibitory interactions between the regulatory p85a subunit and p110d catalytic subunit, leading to a different mechanism of PI3K hyperactivation. Although both mutations have the effect of promoting PtdIns(4,5)P 2 phosphorylation, subtle differences might exist as a result of mislocalization of protein caused by E1021K mutations that have yet to bet determined.
Despite hyperphosphorylation of AKT as a result of both E525K and E1021K mutations, 24 ,25 the effect of gain-offunction mutations on both T and NK cells appears to be one of cellular hyporesponsiveness. This conclusion is supported by our results obtained at the single-cell level by using confocal microscopic image analysis. It is interesting that rarer loss-of-function mutations in PI3K also lead to immunodeficiency and impaired immune responses 23, 48 ; however, the cellular phenotype of NK cells was not specifically studied in these instances. Gain-of-function mutations in PTEN, which would be predicted to have an effect counter to that of PI3K gain-of-function mutations, also lead to a very similar NK cell phenotype. Human NK cells overexpressing PTEN have impaired F-actin accumulation, granule convergence, and MTOC polarization, as seen in patients with APDS1. 49 Interestingly, PI3K inhibitors also impair conjugate formation, cytotoxic function, and MTOC polarization. 50 This effect underscores the importance of carefully regulated PtdIns(4,5) P 2 and PtdIns(3,4,5)P 3 signaling in NK cell cytotoxic function and suggests that deregulation of this signaling globally leads to hyporesponsiveness. In T cells this hyporesponsiveness is likely due to premature senescence of the effector population. However, because NK cell senescence is poorly defined, it is difficult to draw a parallel.
The similarities between loss-and gain-of-function mutations in terms of NK cell phenotype suggests that overactivation of this signaling pathway leads to an inability to tune its responsiveness and might be as detrimental as inactivation through loss of function. This signaling can be restored partially through dampening hyperactive signaling, and inhibition of mTOR signaling is effective in partial restoration of NK cell function in these patients. Treatment with rapamycin in our cohort led to increased cytotoxic function with increased F-actin accumulation at the NK cell synapse, a critical step in NK cell cytotoxicity. Interestingly, this was independent of reversal of the phenotypic changes we detected in patients' NK cells, suggesting that it might represent partial restoration of intracellular activation that has been rendered hyporesponsive in NK cells from patients with APDS.
Although the exact mechanism of action is not known, the known importance of the PI3K signaling pathway through AKT and mTOR in NK cells suggests that retuning responsiveness to cytokine or activating receptor signaling might enable restoration of function in patients' cells. mTOR plays a role in both the generation and activation of NK cells, and primary human cells from healthy donors treated with rapamycin have impaired cytotoxic function, suggesting a direct role for mTOR signaling in the regulation of lytic function. 51 Taken together, our data confirm speculation 29 that extreme susceptibility to herpesviral infection in patients with APDS is due in part to impaired NK cell function and provides additional rationale for the use of rapamycin in patients, particularly those with viral illness.
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